Synthetic self-adjuvanting glycopeptide cancer vaccines

Area of Science:

• Immunology
• Glycobiology
• Oncology

Background:

• Cancer cells exhibit altered glycosylation, presenting tumor-associated carbohydrate antigens (TACAs).
• TACAs are promising targets for cancer vaccines due to their distinct expression on malignant cells.

Purpose of the Study:

• To review the current advancements in developing synthetic self-adjuvanting vaccines targeting TACAs.
• To explore the use of MUC1 and various Toll-like receptor (TLR) agonists in cancer vaccine design.

Main Methods:

• Review of literature on self-adjuvanting glycopeptide cancer vaccines.
• Focus on vaccines incorporating antigenic glycopeptides and adjuvant moieties within a single molecule.
• Discussion of adjuvants including lipopeptide- and lipoamino acid-based TLR2 agonists, and TLR9/TLR4 agonists.

Main Results:

• Self-adjuvanting vaccines predominantly utilize MUC1 as the TACA target.
• Lipophilic adjuvants, such as TLR2 agonists, are commonly conjugated to peptides, forming amphiphilic vaccine molecules.
• These amphiphilic structures may self-assemble into higher-order structures, potentially enhancing in vivo efficacy.

Conclusions:

• Synthetic self-adjuvanting vaccines represent a promising strategy for cancer immunotherapy by targeting TACAs.
• The design of amphiphilic glycopeptide vaccines, particularly those targeting MUC1, is advancing cancer vaccine development.
• Further research into the self-assembly properties of these vaccines could optimize their therapeutic potential.